Experimental brain tumor combo shows promise but trial halted early
NCT ID NCT02942264
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called zotiraciclib (TG02) combined with the standard chemotherapy temozolomide in adults with recurrent anaplastic astrocytoma or glioblastoma. The goal was to find the safest dose and see if the combination worked better than temozolomide alone. The trial was terminated early, so we have limited data on effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zotiraciclib (TG02) and Temozolomide
- What this could lead to
- If successful, this combination could offer a new treatment option for people with recurrent brain tumors, potentially slowing disease progression.
- What could go wrong
- The trial was terminated early with only 53 participants, so results are limited. It is unclear if the combination is better than standard treatment, and side effects may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC ASTROCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields